PUBLISHER: Grand View Research | PRODUCT CODE: 1300996
PUBLISHER: Grand View Research | PRODUCT CODE: 1300996
The global dermatology CRO market size is expected to reach USD 8,057.9 million by 2030, registering a CAGR of 6.8% over the forecast period, according to a new report by Grand View Research, Inc. Rising influx of contract research organizations (CROs) to mitigate the disease burden associated with dermatological conditions is a key driver for this market. Moreover, the rising demand for topical dermatological medications, such as anti-infective, anti-inflammatory agents, local anesthetics, emollients, and cleansers, to cure acne are major factors driving the market growth. High demand for speedy diagnosis, an increase in the prevalence of skin cancer and other skin problems, and increased awareness regarding skin diseases are major factors boosting the market growth.
An increase in cases of skin disease across the globe is expected to propel the market growth in the forecast period. Atopic dermatitis is one of the most common inflammatory skin diseases, affecting around 5-10% of individuals in the U.S. Around one in three individuals in the country with atopic dermatitis have moderate-to-severe disease. Moreover, skin cancer is the most common cancer in the U.S. According to the American Academy of Dermatology, around 1 in 5 individuals would develop skin cancer in their lifetime. In addition, it is estimated that around 9500 individuals in the country are diagnosed with skin cancer every day. The COVID-19 pandemic significantly impacted the market.
Clinical trials in numerous therapeutic fields, including dermatology, were impacted by the COVID-19 pandemic. Several clinical trials were temporarily delayed or halted, impacting the timelines and progress of research studies. This disruption is expected to affect the growth and revenue of dermatology CROs, as their services are closely tied to clinical trial activities. Furthermore, patent expiration in the dermatology industry and growing investment in R&D programs are key factors anticipated to drive market growth in the coming years. For instance, in February 2022, Recipharm acquired CDMO Arranta Bio to expand its mRNA biologics offerings in the U.S. This acquisition is expected to improve the company's capabilities in developing medications in the area of cancer, psoriasis, infectious diseases, and other diseases.